EUCTR2004-002641-12-GB进行中（未招募）1 期
A multicenter, multinational, phase 3b, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson's disease
Schwarz Biosciences GmbH0 个研究点目标入组 220 人开始时间: 2005年6月30日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subject is informed and given ample time and opportunity to think about her/his
- •participation and has given her/his written informed consent.
- •2. Subject is willing and able to comply with all trial requirements.
- •3. Subject has completed Study SP824, SP825, or SP826.
- •4. Subject, in the opinion of the investigator, would benefit from long-term treatment
- •of rotigotine.
- •Are the trial subjects under 18?
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subject has an ongoing serious adverse event that is assessed as related to
- •study medication
研究者
相似试验
进行中（未招募）
不适用
A multicenter, multinational, phase 3b, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson's diseaseParkinson's diseaseEUCTR2004-002641-12-ATSchwarz Biosciences GmbH220
进行中（未招募）
1 期
A multicenter, multinational, phase 3b, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson's diseaseParkinson's diseaseEUCTR2004-002641-12-ESSchwarz Biosciences GmbH220
进行中（未招募）
不适用
A multicenter, multinational, phase 3B, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson s diseaseEUCTR2004-002641-12-ITSCHWARZ PHARMA220
进行中（未招募）
不适用
A multicenter, multinational, phase 3b, open label extension trial, to evaluate the long term effect of the 24 hour transdermal delivery of rotigotine on motor function, sleep quality, and nocturnal and non motor symptoms in subjects with idiopathic Parkinson disease. - SP915, Long term extension of RECOVERPatient with Idiopathic Parkinson DieseaseMedDRA version: 9.1Level: LLTClassification code 10061536Term: Parkinson's diseaseEUCTR2006-006907-35-ITSCHWARZ PHARMA270
进行中（未招募）
不适用
A multi-center, multinational, phase 3, open-label extension trial to assess the safety of long term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinsons disease who are not well controlled on levodopaAdvanced stage Parkinson's DiseaseEUCTR2004-000148-26-ITSCHWARZ PHARMA360